BioSpace News Archive

Foundation Medicine, Inc., today announced the appointment of Dr. Geoffrey R. Oxnard as vice president, global medical lead for the Company’s liquid biopsy portfolio, effective immediately.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported the success of its initiative to conduct safe patient screenings remotely using telehealth technologies.

Building on Merck for Mothers’ Efforts, Initiative Bolsters Support for Locally Created Solutions to Improve Maternal Health and Narrow Disparities During the COVID-19 Pandemic and Beyond KENILWORTH, N.J.--( BUSINESS WIRE )-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it was expanding its Safer Childbirth Cities initiative, a multi-year effort to improve U.S. maternal health outcomes. Safer Childbirth Citie

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment. ADX-2191 is an investigational therapy in clinical development in the U.S. for the prevention of proliferative vitreoretinopathy (PVR), a rare but serious sight-threatening retinal disease with no approved treatment. PVR is

Teva to Present New Data on AJOVY ® (fremanezumab-vfrm) Injection Open-Label Extension Study at American Headache Society Annual Meeting

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the AACR Virtual Annual Meeting II, taking place June 22-24, 2020. Details of the presentation are as follows: Presentation Title: ALPN-202 combines checkpoint inhibition with co

Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology Annual Meeting.

Bayer announced today the initiation of the FINEARTS-HF study, a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of investigational finer

Nihon Kohden, a U.S. market leader in precision medical products and services, announced that it has been named a great workplace for the fifth year in a row by the Great Place to Work® Institute, the global authority on high-trust, high-performance workplace cultures.

International, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with SARS-CoV-2 (COVID-19) Novel Mechanism of Action - a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage Study also recently approved in Canada, additional filings made and planned globa